Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients.
Alan R SchwartzLaura HerpelRichard BoganBruce CorserHuy PhoLuigi Taranto MontemurroPublished in: Sleep & breathing = Schlaf & Atmung (2024)
Both ato-spiro and ato alone decreased OSA severity similarly, but ato-spiro led to even greater, statistically significant and clinically meaningful falls in systolic and diastolic BP. BP reductions were likely due to ato-related improvements in upper airway patency and hypoxemia, and to spiro-related reduced fluid retention. These findings show promise for ato-spiro as an oral treatment for hypertensive OSA patients. REGISTERED AT CLINICALTRIALS.GOV: NCT04905979.
Keyphrases
- blood pressure
- hypertensive patients
- obstructive sleep apnea
- positive airway pressure
- heart rate
- end stage renal disease
- ejection fraction
- left ventricular
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- attention deficit hyperactivity disorder
- prognostic factors
- heart failure
- machine learning
- drug induced
- patient reported
- big data
- working memory